HK1259190A1 - 嵌合抗原受体相关的方法和组合物 - Google Patents

嵌合抗原受体相关的方法和组合物

Info

Publication number
HK1259190A1
HK1259190A1 HK19101243.2A HK19101243A HK1259190A1 HK 1259190 A1 HK1259190 A1 HK 1259190A1 HK 19101243 A HK19101243 A HK 19101243A HK 1259190 A1 HK1259190 A1 HK 1259190A1
Authority
HK
Hong Kong
Prior art keywords
protein
domain
cells
interaction domain
cell
Prior art date
Application number
HK19101243.2A
Other languages
English (en)
Chinese (zh)
Inventor
威尔逊‧翁
威爾遜‧翁
赵章桓
趙章桓
Original Assignee
波士顿大学董事会
波士頓大學董事會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 波士顿大学董事会, 波士頓大學董事會 filed Critical 波士顿大学董事会
Publication of HK1259190A1 publication Critical patent/HK1259190A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
HK19101243.2A 2015-11-23 2016-11-22 嵌合抗原受体相关的方法和组合物 HK1259190A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258712P 2015-11-23 2015-11-23
US62/258,712 2015-11-23
PCT/US2016/063257 WO2017091546A1 (en) 2015-11-23 2016-11-22 Methods and compositions relating to chimeric antigen receptors

Publications (1)

Publication Number Publication Date
HK1259190A1 true HK1259190A1 (zh) 2019-11-29

Family

ID=58764335

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101243.2A HK1259190A1 (zh) 2015-11-23 2016-11-22 嵌合抗原受体相关的方法和组合物

Country Status (7)

Country Link
US (2) US11530252B2 (https=)
EP (1) EP3380602A4 (https=)
JP (1) JP7621053B2 (https=)
KR (2) KR20180075689A (https=)
CN (1) CN108495927A (https=)
HK (1) HK1259190A1 (https=)
WO (1) WO2017091546A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US11091546B2 (en) * 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
US11701387B2 (en) 2018-01-04 2023-07-18 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for BDCA2 antigen
WO2019152957A1 (en) * 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
EP3775902B1 (en) 2018-04-04 2023-02-22 F. Hoffmann-La Roche AG Diagnostic assays to detect tumor antigens in cancer patients
WO2019195759A1 (en) * 2018-04-05 2019-10-10 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
KR20210003780A (ko) 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. Axl 키나제 억제제 및 그의 용도
WO2019222642A1 (en) * 2018-05-18 2019-11-21 Senti Biosciences, Inc. Engineered immune cells and methods of use
EP3836944A4 (en) * 2018-08-16 2022-05-11 Memorial Sloan Kettering Cancer Center LEUCINE ZIPPER BASED COMPOSITIONS AND METHODS OF USE
EP4588483A3 (en) * 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN119752797A (zh) * 2019-01-22 2025-04-04 北京大学深圳研究生院 天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
ES3051182T3 (en) 2019-01-23 2025-12-26 Miltenyi Biotec Bv & Co Kg A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
WO2020201527A1 (en) 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
CN110151999A (zh) * 2019-05-22 2019-08-23 中国人民解放军第四军医大学 用于抑制恶性黑色素瘤进展的靶向药物
CA3142108A1 (en) 2019-05-28 2020-12-03 Miltenyi Biotec B.V. & Co. KG Method for generation of genetically modified t cells
WO2021007580A1 (en) 2019-07-11 2021-01-14 Valkyr, Inc. System and methods relating to chimeric autoantibody receptors
WO2021047804A1 (en) 2019-09-11 2021-03-18 Miltenyi Biotec B.V. & Co. KG In vitro method for transduction of t cells in the presence of malignant cells
JP2023500799A (ja) 2019-10-18 2023-01-11 トラスティーズ オブ ボストン ユニバーシティ Ｃａｌ－ｔコンストラクトおよびその使用
CN115052887B (zh) 2019-12-11 2026-03-31 A2生物治疗公司 基于lilrb1的嵌合抗原受体
WO2021143826A1 (zh) * 2020-01-17 2021-07-22 信达生物制药(苏州)有限公司 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
CN111234033B (zh) * 2020-01-21 2021-05-11 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
CN115298209A (zh) * 2020-02-20 2022-11-04 森迪生物科学公司 抑制性嵌合受体构造体
EP4107175A4 (en) * 2020-02-20 2024-03-20 Senti Biosciences, Inc. ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
CA3171906A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
US20210322471A1 (en) * 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021226289A2 (en) * 2020-05-05 2021-11-11 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
WO2021234006A1 (en) 2020-05-20 2021-11-25 Miltenyi Biotec B.V. & Co. KG Compositions and methods for treating cancer expressing cd90 and cd326
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
BR112023003036A2 (pt) 2020-08-19 2023-04-25 Astellas Pharma Inc Região fc modificada de ocorrência não natural humana de igg especificamente ligando-se a receptor de fc modificado de ocorrência não natural
IL300500A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer
CA3188867A1 (en) 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
WO2022040444A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
EP4210733B1 (en) 2020-09-04 2024-11-06 Miltenyi Biotec B.V. & Co. KG System for inducible expression of an adapter in immune cells
WO2022081841A1 (en) * 2020-10-16 2022-04-21 Fred Hutchinson Cancer Research Center Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r1
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
JP2024506249A (ja) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
US11819578B2 (en) 2021-10-07 2023-11-21 Trustees Of Boston University Nanofiber scaffolds
WO2023062113A1 (en) 2021-10-15 2023-04-20 Miltenyi Biotec B.V. & Co. KG Method for the generation of genetically modified nk cells
US20250255959A1 (en) 2022-04-01 2025-08-14 Miltenyi Biotec B.V. & Co. KG A system for drug-inducible expression of a polynucleotide
WO2023217796A1 (en) 2022-05-10 2023-11-16 Miltenyi Biotec B.V. & Co. KG Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
US20250339464A1 (en) 2022-05-16 2025-11-06 Miltenyi Biotec B.V. & Co. KG Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
EP4342488A1 (en) 2022-09-26 2024-03-27 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for folate receptor 1
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
CN120548367A (zh) 2022-11-18 2025-08-26 波士顿大学董事会 自复制rna及其用途
EP4471067A1 (en) 2023-06-01 2024-12-04 Miltenyi Biotec B.V. & Co. KG A chemically inducible heterodimerizing system and a method for generation thereof
WO2025008108A1 (en) 2023-07-06 2025-01-09 Miltenyi Biotec B.V. & Co. KG Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
EP4545963A1 (en) 2023-10-26 2025-04-30 Miltenyi Biotec B.V. & Co. KG Method for selecting antigen recognizing moieties having specificity for a target structure
WO2025224123A1 (en) 2024-04-25 2025-10-30 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptors specific for fibroblast activation protein
WO2025252325A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
WO2025252326A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233125B2 (en) * 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
DK2956175T3 (da) * 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof

Also Published As

Publication number Publication date
WO2017091546A1 (en) 2017-06-01
JP7621053B2 (ja) 2025-01-29
EP3380602A1 (en) 2018-10-03
EP3380602A4 (en) 2019-09-25
US11530252B2 (en) 2022-12-20
JP2018538277A (ja) 2018-12-27
US20230203123A1 (en) 2023-06-29
KR20250134209A (ko) 2025-09-09
US20180346541A1 (en) 2018-12-06
US12577288B2 (en) 2026-03-17
KR20180075689A (ko) 2018-07-04
CN108495927A (zh) 2018-09-04

Similar Documents

Publication Publication Date Title
US12577288B2 (en) Methods and compositions relating to chimeric antigen receptors
US10881711B2 (en) Anti-CSPG4 reagents and methods of treating cancer
US8753640B2 (en) MIC-binding antibodies and methods of use thereof
JP6585041B2 (ja) 免疫細胞の能力を増強する方法
TW201827597A (zh) 利用嵌合抗原受體之癌症治療
US12559557B2 (en) Methods and compositions relating to anti-PD1 antibody reagents
JP2022502074A (ja) 改変された腫瘍溶解性ウイルス、組成物、およびその使用
JP2024514149A (ja) ｕＰＡＲを標的とするＣＡＲ－Ｔ細胞及びその使用
US20240374644A1 (en) Herv-k antibody therapeutics
US11623953B2 (en) Antibody constructs and methods of treating cancer
KR20240005850A (ko) Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는키메라 항원 수용체
JP2021505659A (ja) 癌治療のためのｔｒｐｖ６阻害剤および併用療法
TW202547873A (zh) 用於治療微量殘存疾病之ｃｓｆ－１或ｃｓｆ－１ｒ抑制
JP2024517986A (ja) 抗－ＣＤ３００ｃ抗体を利用した併用療法
HK40119948A (zh) 与eva1蛋白质结合的人源化抗体或其功能性片段、抗体药物缀合物和嵌合抗原受体
HK40119929A (zh) 抗ccr8抗体及其用途
CN117897402A (zh) 使用抗cd300c抗体的组合疗法
HK40098753A (en) Molecule specifically binding to cldn18.2
CN115335123A (zh) 人4-1bb激动剂抗体及其使用方法